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ORIGINAL ARTICLE
OCTANE (Ontario-wide Cancer Targeted 
Nucleic Acid Evaluation): a platform for  
intraprovincial, national, and international 
clinical data-sharing
E.R. Malone mb bch bao msc,* R.R. Saleh md msc,* C. Yu msc,* L. Ahmed bsc,* T. Pugh phd,*  
J. Torchia phd,* J. Bartlett phd,* C. Virtanen msc,* S.J. Hotte md msc,† J. Hilton md,‡ S. Welch md,§  
A. Robinson md,|| E. McCready phd,† B. Lo md phd,‡ B. Sadikovic phd,§ H. Feilotter phd,||  
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ABSTRACT
Cancer is a genetic disease resulting from germline or somatic genetic aberrations. Rapid progress in the field of 
genomics in recent years is allowing for increased characterization and understanding of the various forms of the 
disease. The Ontario-wide Cancer Targeted Nucleic Acid Evaluation (octane) clinical trial, open at cancer centres 
across Ontario, aims to increase access to genomic sequencing of tumours and to facilitate the collection of clinical 
data related to enrolled patients and their clinical outcomes. The study is designed to assess the clinical utility of 
next-generation sequencing (ngs) in cancer patient care, including enhancement of treatment options available to 
patients. A core aim of the study is to encourage collaboration between cancer hospitals within Ontario while also 
increasing international collaboration in terms of sharing the newly generated data. The single-payer provincial 
health care system in Ontario provides a unique opportunity to develop a province-wide registry of ngs testing and 
a repository of genomically characterized, clinically annotated samples. It also provides an important opportunity 
to use province-wide real-world data to evaluate outcomes and the cost of ngs for patients with advanced cancer.
The octane study is attempting to translate knowledge to help deliver precision oncology in a Canadian 
environment. In this article, we discuss the background to the study and its implementation, current status, and 
future directions.
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BACKGROUND
Cancer arises from inherited or somatic dna alterations 
that lead to host cells undergoing neoplastic transformation, 
proliferation, invasion, and metastasis. Next-generation 
sequencing (ngs) can identify oncogenic driver mutations 
that will highlight targets for genotype-matched drug 
treatment, known as “precision medicine.” Recently, sev-
eral Ontario cancer centres integrated their targeted clin-
ical ngs testing for specific cancer indications. However, 
those ngs testing initiatives have been implemented inde-
pendently across various sites, using a range of technologic 
platforms and limited infrastructure for data-sharing 
between clinical laboratories. Additional challenges, such 
as uncertainty about the optimal size and content of the 
ngs gene panels being used, identification of clinically ac-
tionable genes and mutations, reimbursement for testing 
by the public health care system, and access to matched 
targeted therapy have limited the effect of ngs testing.
The impact (Integrated Molecular Profiling in Ad-
vanced Cancers Trial) and compact (Community Molecular 
Profiling in Advanced Cancer Trial) prospective genomic 
profiling studies were conducted at the Princess Margaret 
Cancer Centre (pmcc) from 2012 to 2015. Those studies used 
a multiplex hotspot mutation panel (23 genes, 279 variants) 
or a targeted ngs panel (approximately 50 genes) to provide 
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molecular characterization data for patients with advanced 
solid tumours to help guide the clinical decision-making 
of their oncologists. Results from the first 1893 patients 
enrolled showed that only 5% of the patients profiled were 
subsequently treated on genotype-matched clinical trials, 
with a response rate higher in that selected group than in 
patients treated on non-genotype-matched trials1.
Despite the growing interest in ngs testing in oncology, 
there are disparities between the demand for and the access 
to this new technology. In Ontario, the only publicly funded 
disease-specific indications for somatic tumour mutation 
testing are ALK and EGFR for non-small-cell lung cancer; 
KRAS, NRAS, and BRAF for colorectal cancer; BRCA1/2 for 
high-grade serous ovarian cancer; and BRAF for malignant 
melanoma. Support for broader-panel ngs testing in aca-
demic institutions has been obtained largely using internal 
laboratory budgets, peer-reviewed grants, and philanthropic 
sources. In the process of generating evidence to inform 
decisions about reimbursement for ngs testing for broader 
indications, the collective experience of molecular charac-
terization across the province has a key role to play. The goal 
of the Ontario-wide Cancer Targeted Nucleic Acid Evaluation 
(octane) study is to develop a provincial registry of ngs 
panel-based testing results, and a repository of genomically 
characterized and clinically annotated tumour tissues and 
blood samples for future research.
Study Design
A prospective trial, octane is enrolling patients with in-
curable solid tumours at the pmcc, the Juravinski Cancer 
Centre, the London Health Sciences Centre, The Ottawa 
Hospital Regional Cancer Centre, and the Kingston General 
Hospital. Eligible patients must meet these criteria:
 n age 18 years or older,
 n Eastern Cooperative Oncology Group performance 
status 0 or 1,
 n adequate organ function,
 n 2 or fewer prior lines of therapy for systemic disease,
 n life expectancy greater than 6 months, and
 n ability to provide informed consent.
The protocol was approved by the Ontario Cancer 
Research Ethics Board (see NCT02906943 at https://
ClinicalTrials.gov/). Study participants donate tumour 
tissue for ngs testing and future research, provide blood 
samples, and grant access to medical health records and 
their ohip (Ontario Health Insurance Plan) number to link 
to provincial health administrative databases for future 
research (Figure 1). Participants agree to de-identified 
clinical and genomic data-sharing for research.
Patient Enrolment
As of 21 January 2019, 2106 patients had been enrolled into 
octane: 1469 at pmcc, 222 at the London Health Sciences 
Centre, 194 at The Ottawa Hospital Regional Cancer Centre, 
101 at the Juravinski Cancer Centre, and 120 at the Kingston 
General Hospital. To date, 69% of the 2106 octane partic-
ipants are women, and the most common tumour types 
are cancers of the ovary (23%), uterus (12%), bowel (12%), 
breast (10%), and lung (5%). All clinical testing is performed 
at laboratories certified and licensed for targeted ngs by the 
Institute for Quality Management in Healthcare.
Targeted ngs testing results for genes that are either 
not routinely reported, or that are reported through local 
molecular tumour boards, are recorded in a secure Web-
based research portal that can be accessed by the patient’s 
treating physician. Blood samples (approximately 20 mL) 
collected from patients and formalin-fixed paraffin- 
embedded tissue blocks or unstained slides for research 
are transferred to a centralized bio-repository maintained 
by the Tissue Portal at the Ontario Institute for Cancer 
Research (oicr). For each participant, information about 
11 essential clinical variables [Table i, modelled after genie 
(Project Genomics Evidence Neoplasia Information 
Exchange) from the American Association of Cancer Re-
search] is collected from review of medical records2. Clin-
ical data are stored using Rave EDC (Medidata, New York, 
NY, U.S.A.), a Web-based electronic data capture system 
hosted by Research Information Systems at the University 
Health Network.
Data Visualization
A local installation of cBioPortal3,4, an open-source Web-
based portal developed by Memorial Sloan Kettering 
Cancer Center, was established for octane. cBioPortal was 
selected because the application is open source and pro-
vides an easy-to-navigate visualization platform that can 
FIGURE 1  OCTANE study data and sample flow. (Item A) Within On-
tario hospitals, patients are identified and consent to enrol in the study. 












uploaded to the cBioPortal.
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integrate clinical and genomic data. Investigators and study 
personnel can visualize genomic variants linked to clinical 
data for queries at the cohort (Figure 2) and individual 
patient (Figure 3) levels. Clinical annotation for genomic 
variants is provided by OncoKB (https://oncokb.org/#/), a 
research data repository that includes 477 cancer genes5. 
For each curated variant, information about biologic ef-
fect, prevalence in a particular tumour type and across all 
tumours, prognostic implications, and treatment options 
are collected. Treatment information is classified using the 
levels-of-evidence system, which assigns clinical action-
ability to individual mutational events and enables clinical 
decision-making about potential treatment options5.
Clinical Translation
Treatment options for patients with clinically actionable 
variants outside the approved indications are being investi-
gated in early-phase clinical trials or the Canadian Cancer 
Trials Group captur study (see NCT03297606 at https://
ClinicalTrials.gov/). A phase ii basket trial (a type of trial 
that tests the effect of one drug on a single mutation in a 
variety of tumour types), captur aims to test the activity 
of commercially available targeted agents in patients who 
have undergone tumour profiling. Currently, 11 approved 
treatments from 4 pharmaceutical partners are given 
alone or in combination. As of March 2019, 54 patients had 
been enrolled across Canada, including 28 from pmcc, 12 
from the London Health Sciences Centre, and 1 from The 
Ottawa Hospital Regional Cancer Centre. The study has 
been active at Kingston General Hospital since February 
2019, but is not yet active at the Juravinski Cancer Centre. 
The captur study is one of a series of similar basket trials 
currently underway, including the American Society of 
Clinical Oncology’s tapur [Targeted Agent and Profiling 
Utilization Registry (NCT02693535)] and the Netherland’s 
drup [Drug Rediscovery Protocol (NCT02925234)]. Ulti-
mately, data sharing by those trials is planned, with the 
objective of providing additional power to examine rare 
tumour genotype–drug matches.
Clinical NGS Testing
Each laboratory uses ngs panels relevant to their site and 
to the ngs platform available. Two panels are used at pmcc: 
a custom hybridization capture panel [SureSelect (Agilent, 
Santa Clara, CA, U.S.A.)] of 555 cancer-relevant genes se-
quenced on a NextSeq series sequencing system (Illumina, 
San Diego, CA, U.S.A.), and more recently, a commercial 161-
gene amplicon dna/rna panel (Oncomine Comprehensive 
Assay v3: ThermoFisher Scientific, Waltham, MA, U.S.A.) se-
quenced on the Ion S5 XL platform (ThermoFisher Scientific). 
The other 4 sites are currently using the Ion AmpliSeq Cancer 
Hotspot Panel v2 (50 genes) on the ThermoFisher platform, 
and there are plans to transition those sites to larger ngs 
panels. To develop a robust infrastructure for clinical and 
genomic data-sharing across the province, 5 academic can-
cer centres were initially selected to participate in octane. 
There is currently an open call to expand octane to include 
2–3 additional participating sites over the next year.
Additional Genomic Characterization
All blood and archival tissue samples undergo dna/rna 
co-isolation before banking. After approval by the octane 
steering committee, selected cases undergo further analy-
sis at the pmcc oicr Translational Genomics Laboratory 
(https://labs.oicr.on.ca/translational-genomics-laboratory). 
An ongoing research project involves whole-exome se-
quencing and transcriptome and methylation profiling in 
cases in which an oncogenic driver is not identified through 
targeted ngs panel testing. To date, 74 patients in that cat-
egory have been profiled by the Translational Genomics 
Laboratory. This ongoing project will provide evidence for 
when more comprehensive profiling can inform clinical 
decision-making in selected patients with cancer.
TABLE I Required clinical variables for OCTANE2 per Project GENIE 




 n Cancer typea
 n Date of diagnosis
 n Site of sample being profiled (primary or metastasis)
 n Date of sample collection
 n Date of sequencing results
 n Standard molecular pathology information
 n Relevant past medical history










histologic  subtype of  the cancer.  (Item G) The distribution of age at 
diagnosis. (Item H) The sex of the enrolled patients. Other options for 
graphical representation are also available. Courtesy of cBioPortal 3,4.
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Collaboration Efforts and Data Sharing
The American Association of Cancer Research genie 
international data-sharing project (https://www.aacr.
org/Research/Research/pages/aacr-project-genie.aspx) 
catalogs cancer genomic data and clinical outcomes from 
the cancer sequencing efforts of multiple international 
institutions2. As one of the 8 founding-member institutions 
of genie, pmcc is sharing results from the octane study 
with genie. To date, the genie dataset includes more than 
60,000 de-identified genomic records from 19 member 
institutions, including 756 from octane. The repository 
will continue to grow as more patients are treated at par-
ticipating institutions and as new centres join the project.
The oicr is a founding member of the International 
Cancer Genome Consortium’s Accelerating Research in 
Genomic Oncology project (https://icgcargo.org/)6. The 
Consortium provides a forum for collaboration between 
leading cancer and genomic researchers. The Accelerating 
Research in Genomic Oncology project aims to analyze 
genomic data together with high-quality longitudinally 
collected clinical data from 100,000 cancer patients (life-
style; patient history; cancer diagnostic data; treatment; 
and outcomes, including response to, and survival after, 
treatment). The octane study will provide a framework for 
patients across the province to participate in the project, 
with comprehensive sequencing of their tumours and 
longitudinal clinical data collection.
Clinical Trial Matching
Busy practicing oncologists can consider it challenging to 
identify appropriate therapeutic clinical trials available 
for their patients with potentially actionable genomic 
alterations. MatchMiner (https://matchminer.org/) was 
developed at the Dana–Farber Cancer Institute as an open-
source computational platform for matching patient-specific 
genomic and clinical data with structured eligibility criteria 
for clinical trials7. The platform matches patient-specific 
genomic variants with clinical trials and makes the results 
available to investigators and clinicians on a Web-based 
platform. The system is currently being integrated into 
cBioPortal at pmcc and should ease the process of matching 
patients to suitable trials by flagging patients with actionable 
matching mutations.
Liquid Biopsy
Small fragments of tumour dna released into the blood-
stream, known as circulating tumour dna, allow for detec-
tion of tumour-specific dna mutations in a peripheral blood 
sample. Characterization of circulating tumour dna by ngs 
can now be used to guide tumour-specific therapy and might 
be particularly profitable in patients with scant archival 
tumour material available or lesions difficult to biopsy. A 
number of private vendors have developed liquid biopsy 
testing platforms. In the future, octane or similar initiatives 
will have to evolve to incorporate this diagnostic technology.
Evaluate the Clinical Impact of Genomic Testing
Precision medicine—the use of results from multigene 
ngs panel testing to tailor treatment for patients with 
advanced cancers—has attracted the criticism that evi-
dence for improved outcomes from the tailored treatment 
is lacking8 (Table ii). In the United States, the Centers for 
Medicare and Medicaid Services recently announced a 
national coverage determination that includes expanded 
coverage for ngs tests to be used as companion diagnostics 
for all patients with advanced cancer16. The initial funding 
proposal17 included a Genetic Testing Registry to collect 
information relating to patient and cancer characteristics, 
outcomes data (overall survival, progression-free survival, 
objective response rate), and patient-reported outcomes. 
The subsequent policy document did not include a man-
datory requirement for a registry to evaluate outcomes18. 
That decision has been criticized as a missed opportunity 
to collect valuable information about the clinical utility of 
ngs testing16. As a result, studies that collect information 
about clinical outcomes related to ngs testing, such as 
octane, are vitally important to fill the information gap.
Evaluating Real-World Data
The linkage of octane to Ontario administrative data 
sources through ices provides an opportunity to assess the 
real-world clinical utility and cost-effectiveness of ngs in 
the context of Ontario’s publicly funded health care system. 
As an independent not-for-profit research institute, ices 
uses encoded, linked population-based data collected from 
individual patients in Ontario to provide scientific insights 
into the provincial health care system that could not be 
otherwise be generated. Real-world data—the ices data 
being one example—is health care information derived 
FIGURE 3  cBioPortal dashboard for patient-level data. (Item A) This 
image represents the summary overview for a patient. Other tabs provide 
options for displaying only mutation data, copy number alterations, and 
clinical information. (Item B) This section of the dashboard provides 
a  genomic overview.  (Item C)  Shows  all  the mutations  present,  the 
genes involved,  the resultant protein changes, whether the mutation 




and the alteration frequency in the cohort. Courtesy of cBioPortal3,4.
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from multiple sources outside typical clinical research 
settings19. Those data are collected from electronic health 
records, physician claims datasets, disease registries, and 
other health data repositories in multiple institutions and 
clinics. The resulting analyses can provide information that 
complements traditional clinical trials. Follow-up might be 
longer than would be possible in some clinical trials, and 
completeness for key health encounters such as hospital-
izations and emergency department visits can be more 
comprehensive20. Information gathered concerning subse-
quent therapies might also be more complete. Accordingly, 
real-world evidence from ices has guided policymakers, 
managers, planners, researchers, and practitioners in their 
efforts to optimize the provincial health system.
Using linked ices data, the proportion of octane 
patients benefiting from ngs-informed therapy will be 
described, as will the effects of testing on overall survival. 
Health resource use, outcomes, and costs will be compared 
for patients enrolled in octane and matched patients at in-
stitutions not enrolling patients on octane. This use of the 
linked data will allow for the creation of a comprehensive 
picture of health care use and costs in the Ontario system 
based on use of ngs testing.
The real-world effects of ngs test results on clinical 
decision-making will also be assessed in octane by sur-
veying the treating oncologists to ascertain whether ngs 
testing data were used to inform treatment selection and to 
collect information about specific treatments prescribed, 
duration of matched treatment, and the best-response 
outcomes. Treating oncologists will be surveyed at regular 
intervals after a patient’s ngs sequencing results are report-
ed to octane until that patient is known to be deceased. 
For a subset of patients, those data will be compared with 
data garnered through the ices linkage.
SUMMARY
The primary goal of octane is to build broad capacity for 
cancer genetic testing throughout Ontario. The process 
has required collaboration between physicians, scientists, 
informatics experts, and hospital sites across the province. 
Success in making further treatment options available 
to patients will be evaluated over time as patients, in 
increasing numbers, undergo sequencing and have their 
outcomes recorded.
The experience gained through octane can provide 
guidance to other provinces that might be interested in 
undertaking a similar initiative. Several important lessons 
have been learned. Archival tumour samples for many 
patients are very limited, and so the engagement of pa-
thologists is critical to ensure timely retrieval and review 
of available tissue for targeted sequencing and storage in 
the research repository. In routine practice, pathologists do 
not typically use the OncoTree ontology (http://oncotree.
mskcc.org/#/home) for diagnostic reporting, and trained 
personnel are required to map diagnostic pathology terms 
to facilitate data-sharing. Although detection of variants by 
multiple clinical testing laboratories is highly concordant, 
reporting practices vary across sites. For instance, some 
laboratories create a formal report that that includes all 
variants detected on the panel; other sites report variants 
only in genes included on their laboratory testing licenses; 
and still others do not create a report—clinicians access 
research testing results through the octane cBioPortal. 
A flexible approach to participant recruitment, ngs panel 
sequencing, and variant reporting that accounts for local 
differences in practice and research capacity can facilitate 
intraprovincial data-sharing.
The framework used for octane can be translated to 
other provinces and could enable the delivery of precision 
oncology nationwide. The octane collaborative model can 
also be applied to other (non-cancer) disease settings in 
Canada in which the effects of broad-based genetic data are 
uncertain and further data are needed to inform decisions 
about reimbursement within provincial health care systems.
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TABLE II Results of genotype-matching to clinical trials to date
Group Patients tested Platform Genotype-matched trial enrolment
Memorial Sloan Kettering Cancer Center9 12,670 341- to 410-gene panel 527 of 5009 (11%)
(>1 year of follow-up)
Dana–Farber Cancer Institute and 
 Harvard Cancer Center10
3,727 275-Gene panel 16 of 50 (32%)
(year 1)
Cancer Research Center of Lyon11 2,676 69-Gene panel and aCGH 143 of 1,944 (7%)
MD Anderson Cancer Centre12 2,000 11- to 50-gene panel 83 of 2,000 (4%)
Princess Margaret Cancer Centre1 1,640 23- to 48-gene panel 92 of 1,640 (6%)
Institut Gustave Roussy13 1,035 30- to 75-gene panel and aCGH 199 of 1,035 (19%)
University of Michigan14 556 WGS, WES, RNA-Seq 3%–11%
U.S. National Cancer Institute, 
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